Merrimack Pharmaceuticals Inc (MACK): Gewinn- und Verlustrechnung Nicht notiert
Kennzahl in 1000 USD | TTM 2022-12-31 | 2022-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
Umsatz | -445 | -445 | 144.273 | 89.258 | 102.756 | 47.786 | 48.921 | 34.215 | 20.305 | 2.148 |
Herstellungskosten | 445 | 445 | 6.912 | 46 | 138.495 | 164.396 | 137.833 | 100.630 | 58.278 | 37.658 |
Bruttoergebnis | -890 | -445 | 137.361 | 89.212 | 102.756 | 47.786 | 48.921 | -66.415 | -37.973 | -35.510 |
▸ Brutto-Marge | 200% | 100% | 95,21% | 99,95% | 100% | 100% | 100% | -194,11% | -187,01% | -1.653,17% |
Betriebliche Aufwendungen | -283 | 1.284 | 247.502 | 218.783 | 169.012 | 168.326 | 141.663 | 14.454 | 11.203 | 12.178 |
Operativer Gewinn/Verlust | -607 | -1.729 | -110.141 | -129.571 | -66.256 | -120.540 | -92.742 | -80.869 | -49.176 | -47.688 |
▸ Operative Marge | 136,4% | 388,54% | -76,34% | -145,16% | -64,48% | -252,25% | -189,58% | -236,36% | -242,19% | -2.220,11% |
Zinsen (Netto) | - | - | -43.369 | -562 | -18.230 | -10.938 | -553 | -13 | -3.726 | -4.909 |
▸ Zinsausgaben | 118 | 188 | 43.645 | 19.232 | 18.230 | 10.938 | 553 | 13 | 3.726 | 4.909 |
▸ Zinseinnahmen | 118 | 188 | 276 | 18.670 | - | - | - | - | - | - |
Andere Ausgaben | -118 | -188 | 8 | 17.654 | -927 | -793 | -1.541 | -1.206 | -2.743 | -122 |
Gewinn vor Steuern | -489 | -1.541 | -153.518 | -147.787 | -83.559 | -130.685 | -91.754 | -79.676 | -50.159 | -52.475 |
Steueraufwand | 3 | 3 | -13.224 | -3.918 | -3.491 | -2.349 | -4.141 | -440 | 3.671 | -3.402 |
Minderheitenanteil | - | - | 11.446 | 4.088 | 3.223 | 2.589 | 3.664 | -13 | -3.726 | - |
Nettogewinn/-verlust | -492 | -1.544 | -151.740 | -147.957 | -83.291 | -130.925 | -91.277 | -79.223 | -50.104 | -49.073 |
▸ Netto-Marge | 110,56% | 346,97% | -105,18% | -165,76% | -81,06% | -273,98% | -186,58% | -231,54% | -246,76% | -2.284,59% |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.